Business Context and Reporting Period
Neurosense Therapeutics Ltd. filed a Form 6-K on September 9, 2026, for the month of September 2026. The filing announces a corporate action involving a reverse share split of the Company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Share Split: The Company will effect a 1-for-20 reverse share split.
- Share Count Adjustment: Issued and outstanding ordinary shares will decrease from 37,938,036 to 1,896,902 (subject to fractional share rounding).
- Fractional Shares: No fractional shares will be issued; all fractional amounts will be rounded up to the nearest whole share.
- Derivatives Adjustment: A proportionate adjustment will be made to the per-share exercise price and the number of shares issuable for all outstanding warrants and options.
- Trading Resumption: Trading on the Nasdaq Capital Market under the new structure will commence on Monday, September 14, 2026.
- Identification: The new CUSIP number for the ordinary shares is M74240207.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future performance, specific risks, or contingencies beyond the mechanics of the share split. The Company states that its authorized share capital will remain unchanged following the implementation.
Investor Verification Checklist
- Confirm the effective date of the reverse split (September 14, 2026) and the new CUSIP (M74240207).
- Verify the treatment of fractional shares (rounded up) and the impact on personal holdings.
- Check the adjusted exercise prices and share counts for any held options or warrants.
- Review the Company's Form 20-F for the most recent audited financial statements, as this 6-K contains no financial data.